Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions View by Topic View by Date Must Reads In Cellular Therapy Cellular Therapy for January/February 2020 CAR T-cell therapy may worsen mental health in some patients, New Toxicity Subscale Measures QOL in Cancer Patients on Checkpoint Inhibitors, CAR T cells produce complete responses in T-cell malignancies, More must reads Cellular Therapy for November/December 2019 CAR T-cell therapy advances in CLL, Inhibitor appears to strengthen anti-BCMA CAR T cells in myeloma patients, PT-Cy bests conventional GVHD prophylaxis, Off-the-shelf cellular therapy shows promise in the lab, Bispecific CAR T-Cells Yield High Response Rate in Relapsed/Refractory Myeloma, More must readsCellular Therapy for September/October 2019 CAR T-Cell Therapy Found Safe, Effective For HIV-Associated Lymphoma, CT103A elicits responses after prior CAR T-cell relapse, More must readsCellular Therapy for May/June 2019 Low intensity bridging may be best path to CAR T in adult ALL, More must readsCellular Therapy for March/April 2019 Gene therapy restored immunity in newly diagnosed SCID-X1, Infant Survival Rate Flat in Infants After HCT, Ixazomib targets treatment failure in chronic GVHD, MRD status at transplant predicts outcomes in ALL patients, Secondary AML in first remission predicts outcomes, More must readsPages1 2 3 4 last »
